INLEXZO gemcitabine intravesical system

Drug Class

Intravesical drug delivery system

Mechanism

Maintains sustained release of gemcitabine directly into the bladder, which is subsequently converted to active metabolites that disrupt DNA synthesis.

Approved Indication

BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, per its FDA approval.

What This Means For Patients

INLEXZO is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2025) — Sources

Pivotal Clinical Evidence

• SunRISe-1 — Daneshmand et al., J Clin Oncol 2025 (NCT04640623) — Sources

Sources

• https://www.jnj.com/media-center/press-releases/johson-and-johnson-announces-fda-approval-of-inlexzo-for-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer
• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218204